TITLE

Vilazodone

AUTHOR(S)
Frampton, James E.
PUB. DATE
July 2011
SOURCE
CNS Drugs;2011, Vol. 25 Issue 7, p615
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Vilazodone, a novel antidepressant agent that combines selective serotonin reuptake inhibitor (SSRI) activity and serotonin 5-HT1A receptor partial agonist activity in a single molecule, is indicated for the treatment of major depressive disorder (MDD) in the US. It is administered orally, once daily, with food. At the recommended dosage of 40 mg/day, vilazodone was effective in the short-term treatment of MDD in adults, as evidenced by significant improvements versus placebo on multiple measures of depression, including the Montgomery-A sberg Depression Rating Scale (MADRS) and the 17-item Hamilton Rating Scale for Depression (HAM-D-17), in two pivotal, 8-week, randomized, double-blind, phase III studies. Significant differences between vilazodone and placebo on the MADRS and HAM-D-17 were seen after 1 week of treatment (first efficacy timepoint) in one of the two studies. Long-term treatment with vilazodone 40mg/day was associated with an improvement from baseline in depressive symptoms in a 52-week, noncomparative, phase III study. Vilazodone was generally well tolerated in the short- and long-term treatment of MDD, with diarrhoea and nausea being the most frequently occurring treatment-emergent adverse events. Vilazodone had a minimal impact on sexual functioning in the three phase III studies. INSET: Features and properties of vilazodone (ViibrydTM).
ACCESSION #
78388099

 

Related Articles

  • Drug Treatments for Patients with Dysthymia. Kripke, Clarissa // American Family Physician;10/1/2004, Vol. 70 Issue 7, p1269 

    Presents information on drug treatments that are effective for dysthymia. Comparison between the efficacy of anti-depressants and placebo; Information on the side effects of tricyclic antidepressants and selective serotonin reuptake inhibitors.

  • Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Peet, Malcolm; Peet, M // British Journal of Psychiatry;Apr94, Vol. 164, p549 

    The rate of treatment-emergent switch into mania has been calculated from all available clinical trial data on the selective serotonin re-uptake inhibitors (SSRIs) fluoxetine, fluvoxamine, paroxetine, and sertraline, relative to comparative groups treated with tricyclic antidepressants (TCAs) or...

  • Duloxetine: A Review of its Use in the Treatment of Major Depressive Disorder. Frampton, James E.; Plosker, Greg L. // CNS Drugs;2007, Vol. 21 Issue 7, p581 

    Duloxetine (Cymbalta) is an orally administered, selective serotonin and noradrenaline reuptake inhibitor (SNRI) that has been approved for the treatment of major depressive disorder (MDD).Based on a considerable body of evidence, duloxetine at dosages ranging from 40 to 120 mg/day was effective...

  • The Future of Depression Psychopharmacology. Belmaker, Robert H. // CNS Spectrums: The International Journal of Neuropsychiatric Med;Aug2008, Vol. 13 Issue 8, p682 

    Along with the development of selective sertonin reuptake inhibitors there has been a tremendous widening of the definition of depression and an impressive decrease in the placebo-drug difference in controlled studies. In the early 1960s, about one third of depressed patients improved with...

  • Neural Correlates of Antidepressant-Related Sexual Dysfunction: A Placebo-Controlled fMRI Study on Healthy Males Under Subchronic Paroxetine and Bupropion. Abler, Birgit; Seeringer, Angela; Hartmann, Antonie; Grön, Georg; Metzger, Coraline; Walter, Martin; Stingl, Julia // Neuropsychopharmacology;Aug2011, Vol. 36 Issue 9, p1837 

    Sexual dysfunction is a common side effect of selective serotonin reuptake inhibitors (SSRIs) like paroxetine in the treatment of depression, imposing a considerable risk on medication adherence and hence therapeutic success. Bupropion, a norepinephrine and dopamine reuptake inhibitor, is...

  • Escitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults. Garnock-Jones, Karly P.; McCormack, Paul L. // CNS Drugs;2010, Vol. 24 Issue 9, p769 

    Escitalopram (escitalopram oxalate; Cipralex®, Lexapro®), a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD), demonstrates a highly selective and potent, dose-dependent inhibition of the human serotonin transporter, inhibiting...

  • A Systematic Review of Antidepressant Placebo-Controlled Trials for Geriatric Depression: Limitations of Current Data and Directions for the Future. Taylor, Warren D.; Doraiswamy, P. Mural // Neuropsychopharmacology;Dec2004, Vol. 29 Issue 12, p2285 

    Depression in the elderly is a major public health problem as untreated depression adversely impacts comorbid illnesses. It is important to develop safe and effective antidepressant therapies for older individuals. We performed a systematic review of all published randomized, placebo-controlled...

  • SSRIs start to relieve depression soon after the start of treatment.  // BMJ: British Medical Journal (International Edition);12/9/2006, Vol. 333 Issue 7580, p1180 

    The article examines how long it takes for selective serotonin reuptake inhibitors (SSRIs) to relieve depression and focuses on a study which looked at published clinical trials that compared SSRI antidepressants with placebo for depressed patients. The authors found that antidepressants work...

  • Initial Effectiveness, Partial Remission, and Full Remission in Depression: Focus on Long-Term Treatment with SNRIs. Dursun, Serdar // CNS Spectrums: The International Journal of Neuropsychiatric Med;Jul2008 Supplement 11, Vol. 13 Issue 7, p10 

    Full remission, defined as the absence of all significant symptoms of depression over at least 6 months, is the ultimate goal of antidepressant therapy. Remission takes time and studies have shown that remission rates continue to rise for at least 3 months after initial improvement. Depression...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics